Dare Bioscience, Inc. (NASDAQ:DARE) a clinical-stage, women biopharmaceutical company, is expected to report third quarter earnings results, before market open, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.17 per share from revenue of $ 0.18 million.
Looking ahead, the full year loss are expected at $ 0.71 per share on the revenues of $ 0.53 million.
Stock Performance
Shares of Dare Bioscience, Inc. traded up $ 0.05 or 4.76 percent on Wednesday, reaching $ 1.10 with volume of 450.60 thousand shares. Dare Bioscience, Inc. has traded high as $ 1.12 and has cracked $ 1.04 on the downward trend
The closing price of $ 1.10, representing a 52.17 % increase from the 52 week low of $ 0.69 and a 52.7 % decrease over the 52 week high of $ 2.22.
The company has a market capital of $ 34.71 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Dare Bioscience, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, (844) 831-3031 or (443) 637-1284 (International), with passcode : 6519434 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.darebioscience.com
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing womens reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy.
